The GLP is committed to full transparency. Download and review our 2019 Annual Report

Bayer asks judge to overturn $80 million glyphosate-cancer verdict, citing evidence excluded from trial

| | June 5, 2019
unnamed file
Plaintiff Edwin Hardeman, right, with his wife Mary. Image: Jeff Chiu/AP
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Lawyers for Monsanto Co.’s parent company, Bayer AG, have asked the federal judge overseeing a batch of lawsuits accusing the company’s blockbuster herbicide Roundup of causing cancer to reverse an $80 million dollar damages verdict in the first case to go to trial in the multidistrict litigation, or to grant the company a new trial.

In court papers filed [May 31], Bayer’s lawyers …. claim the jury’s finding that Roundup use caused Sonoma County resident Edwin Hardeman’s non-Hodgkin lymphoma runs counter to regulatory determinations and scientific evidence showing that glyphosate, the active ingredient in Roundup, doesn’t pose a cancer threat to humans when used properly. Monsanto’s lawyers also argued that U.S. District Judge Vince Chhabria, who is overseeing the Roundup MDL, got several evidentiary rulings wrong.

Related article:  Menopausal hormone therapy linked to breast cancer risk—even after patients stop taking drugs

In particular, Monsanto’s lawyers claim that although plaintiffs were allowed to introduce evidence related to a 2015 finding by a United Nations-related body that glyphosate is “probably carcinogenic” in humans, the company wasn’t allowed to introduce evidence from other regulatory bodies, which have subsequently found Roundup safe to use as directed.

Read full, original article: Monsanto Takes Shot at Reversing $80M Federal Roundup Verdict (Behind Paywall)

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend